Recurrence of Fungal Nail Disease and the Dissociation of Relapse from Re-infection S ir, M easurement of relapse and re-infection rates Although the newer drugs for onychomycosis are more eOE ect-
The essence of the method is to establish the time to ive than their predecessors, they still leave much room for re-appearance of clinical and mycological evidence of disease improvement; we can therefore expect more, if not better, in patients who have had their onychomycosis cured. From drugs. Their gestation will inevitably be subjected to the usual this, a group prevalence of re-appearance of the nail condition battering by tedious double-blind, randomized ''placebo''-and mycological infection can be plotted against time. If controlled studies, procedures which lose as much in underrelapse has any therapeutic signi cance its rate would have to standing as they give in assurance. D rug regulatory agencies be greater than that of re-infection. Therefore we can predict will inevitably ask for comparisons of relapse rate with diOE erent a single curve for recurrence formed by the superimposition drugs, the obvious and necessary information which we should of the discrete curves for relapse and re-infection. Since the have had long ago (1), but still fail to provide. Of course, slope of the cumulative curve for relapse would, by de nition, recurrence rate is essential to the comparison of the e cacy be steeper than that for re-infection, the combination of the of drugs, particularly for chronic infections such as onychotwo curves, which is the plot of the raw data collected for mycosis. But the problem which immediately becomes apparrecurrence, would have a double, camel hump, course. From ent, and which is implicit in the de nition of recurrence, is this cumulative curve of recurrence, the slope of each underthe need to dissociate its twin components: relapse and lying single curve could then be calculated, giving the rates re-infection. Yet awareness of need, let alone understanding for both relapse and re-infection. But, alas, the devil is in the of how it can be achieved, is not listed in the task books of detail, from clinical observation to mycology and study organmycology, pure or applied (2). This paper is an attempt to ization, as will now be discussed. rectify that omission, by considering ways in which these two distinct entities can be measured.
Clinical observations R elapse is simply the re-appearance of the same episode of disease, whatever time has elapsed; re-infection is the D etection of the earliest clinical change of recurrent onychore-appearance of a new episode of the same disease caused by mycosis is in large part guesswork. The main problem with a new infection. If a recurrence is the re-appearance of the clinical assessment of early or minimal disease is its indistinvery same disease by the very same causal organism, this guishability from trivial, non-infective nail changes, which is implies that the disease has never completely gone. The why it is usually given mycological support. N evertheless, the somewhat disturbing alternative is a recrudescence from a nest clinical observation of disease re-appearance has to be made of the original infectious agent that has persisted in the absence independently of mycology with photographic recording, of clinical disease -a reservoir rather than an infection, together with a note of site, severity, causal organism of fungal although, pathologically, this is a re-infection, not a relapse.
disease elsewhere, with evidence of predisposition, such as One of the essential pilot studies, therefore, entails careful fungal load and ease of delivery to the site of infection. structural and mycological studies of nails which have apparently been ''cured'', to establish whether or not there is M ycology persistence of minor pockets of residual disease, or of fungi sequestered without disease. The relative prevalence of these The incomplete reproducibility of microscopic examination of two entities could be critical to the development of a K OH preparations for hyphae, and the even worse reproducirecurrence.
bility of mycological culture, together with the uncertain R e-infection turns out to be no less complex. Only when an signi cance of both after drug therapy (1), seriously limits infection is cured, the causal organism is eradicated and the their value. If, as seems likely, culture is only half as reproduinvolved tissues heal, will the likelihood of new re-infection cible as K OH, if not less, it follows that a minimum of two necessarily be the same as in the general population? If it is independent samples should be used for K OH examination not, there must have been an abnormal propensity for developand four for culture. Of course, all such studies would be ment of the disease either before the infection or subsequent, enormously enhanced by an improved mycological methodand presumably consequent, to it. We therefore need to know ology (1). whether an infective episode decreases the rate of re-infection, as commonly occurs with disease-provoked immunity, or S tudy organization enhances the risk of re-infection from, say, a residual structural abnormality such as secondary nail dystrophy. It is clear that
The study group must be homogeneous for factors which may in uence disease re-appearance, e.g. type (including mycologfor the e cacy of drug treatment of onychomycosis, relapse rather than re-infection will be the major consideration.
ical ) extent of disease, time taken to complete cure and its subsequent duration, and site and nature of fungal disease H aving teased out some of the subtleties of the deceptively innocent de nition of relapse and re-infection from the process elsewhere. Since the group size required must be large enough for group analysis, yet cannot be predicted in advance, the of recurrence, can we now apply the simple working de nition of relapse as a recurrence not due to a re-infection to the study would have to be expanded and analysed continuously, independently of the examining clinician who would need to measurement of both events? Sadly, as will become apparent, this simple method resembles the parental de nitions in having be kept unaware of the cumulative ndings. F inally, either a single drug is used for therapy, or the groups must be large a deceptive simplicity, which in this case hides the problems of clinical observation and mycology.
enough for separate analysis of each drug.
It will be apparent that both the clinical and pathological desirable than likely. What could be done, however, is to use chemical characteristics to de ne a group of patients with the demands of such a study are impossibly excessive, and that a practical compromise would be essential.
same discretely characterizable infections, and then to show whether or not the group size changes with re-appearance of disease.
Other methods

Conclusions
Other methods include carrying out a thorough investigation of nails which have been classi ed as clinically and mycologAlthough the questions we have asked are trivial, the answers, ically cured by drug therapy. The prime purpose would be to and the clinical task in providing them, are surely essential to nd the basis of relapse, since this must be due to a continuing, the development of new drugs which go beyond cure, to the but hidden, focus of disease. Likewise the relationship to this prevention of relapse and re-infection. of a re-infection from a fungal reservoir without infection. To achieve this, ''cured'' nails will have to be re-investigated in R EF EREN CES detail in the rst weeks of ''cure'' and subsequently. This re-investigation would entail repeated examination of nail of onychomycot ic disease. Such a study would include the 2. Baran R , H ay R , H aneke E, Tosti A. Onychomycosis . The current development of a mycology which could de ne with precision approach to diagnosis and therapy. London, M artin D unitz, 1999. both presence and vitality of causally associated fungi (1).
An altogether more interesting methodology would follow 
